

80° Aníversario



MEDICINA (B Aires) - Volumen 79 - (Supl. IV), 2019



COMITÉ DE REDACCIÓN

Pablo J. Azurmendi Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina Damasia Becú Villalobos Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina José H. Časabé Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina Eduardo L. De Vito Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina Isabel Narvaiz Kantor Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina Basilio A. Kotsias Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina Gustavo Kusminsky Hospital Universitario Austral, Buenos Aires, Argentina Isabel A. Lüthy Instituto de Biología y Medicina Experimental (IBYME), Buenos

Daniel A. Manigot Hospital San Juan de Dios, Buenos Aires, Argentina Jorge A. Manni Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina **Rodolfo S. Martin** Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina Guillermo D. Mazzolini Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina Rodolfo C. Puche Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina Viviana Ritacco Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina Guillermo B. Semeniuk Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso Instituto Cardiovascular Rosario, Santa Fe, Argentina Guillermo Jaim Etcheverry Facultad de Medicina, UBA, Argentina

Aires, Argentina

María Marta de Elizalde de Bracco IMEX-CONICET-Academia Nacional de Medicina, Argentina Christiane Dosne Pasqualini Academia Nacional de Medicina, Argentina

La Tapa (Ver pág. 4) Atardecer en la tarde Antonella Ricagni

MEDICINA (Buenos Aires) - Revista bimestral - ISSN 0025-7680 (Impresa) - ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL Registro de la Propiedad Intelectual N° 02683675 Personería Jurídica N° C-7497 Publicación de la Fundación Revista Medicina (Buenos Aires) Propietario de la publicación: Fundación Revista Medicin a Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva. MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina. Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables: Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150, 1427 Buenos Aires, Argentina Tel. 5287-3827 Int. 73919 y 4523-6619 e-mail: revmedbuenosaires@gmail.com – http://: www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019



REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

LXIV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC)

LI Reunión Anual de la Asociación Argentina de Farmacología Experimental (SAFE)

> XXI Reunión Anual de la Sociedad Argentina de Biología (SAB)

XXXI Reunión Anual de la Sociedad Argentina de Protozoología (SAP)

IX Reunión Anual de la Asociación Argentina de Nanomedicinas (NANOMED-ar)

VI Reunión Científica Regional de la Asociación Argentina de Ciencia y Tecnología de Animales de Laboratorio (AACyTAL)

> con la participación de The Histochemical Society

13 - 16 de noviembre de 2019 Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

Dra. Mónica Costas Dra. Gabriela Marino Dr. Pablo Azurmendi tumor apoptotic rate, accelerated tumor progression and impaired the antitumor and antimetastatic effect of chemotherapy suggesting that HN inhibits the response of TNBC cells to cytotoxic stimuli, facilitating tumor progression and chemoresistance. Inhibition of endogenous HN increased apoptosis and chemosensibility of TNBC and glioblastoma cells. In addition, chemotherapeutic drugs increased HN expression. Our results put into question the safety of systemic administration of HN or its analogs for chronic diseases and suggest that local administration of gene therapy vectors that silence endogenous HN could hold therapeutic potential in cancer.

insulin-like growth factor (IGF)-1, as well as

IMPLICATION OF THE PROLIFERATION / APOPTOSIS BALANCE IN OVARIAN ALTERATIONS IN BOVINES

NATALIA SALVETTI

Veterinary Sciences of Litoral (ICIVET). National University of Litoral. Santa Fe, Argentina.

Follicular persistence is caused by the failure of ovulation and the consequent permanence of the follicular structure in the ovary, which alters the cyclicity of the female and causes infertility. This process is one of the main components of cystic ovarian disease (COD) and other diseases of ovarian origin that causes great economic losses in the dairy industry because of unsuccessful artificial inseminations, veterinarv treatment and decrease in milk production related to the increase in the interval from calving to conception. Along folliculogenesis, the cells that compose the ovarian follicles normally proliferate and then differentiate. Finally, the follicle can take one of two pathways: ovulation, if the follicle is dominant in an ovulatory wave, or atresia, which occurs with most of the non-dominant follicles. Successful follicle development depends on the presence of survival factors that promote follicle growth and also protect cells from apoptosis. These include factors produced within the ovary like $17-\beta$ estradiol, progesterone,

gonadotropins. In the absence of survival factors, endogenous apoptotic pathways within the follicle become activated and lead to follicular atresia. Many studies in different species have shown that the processes of proliferation and apoptosis are altered in the cysts already formed, where there is a decrease in cellular proliferation and an increase in the survival of the cells, which contribute to the persistence of these follicles, preventing their ovulation or regression. However, the study of initial events in the development of persistence indicates that, initially, the proliferation rate is maintained in the absence of ovulation, with low levels of apoptosis and an increase in cell survival due to the increase in anti-apoptotic proteins. It is probable that the hormonal changes that occur later, both at endocrine and paracrine level, are responsible for the alterations observed in the parameters of cell proliferation and differentiation of already developed cysts.

SAB SYMPOSIUM III

YOUNG RESEARCHERS

Chairs: Débora Cohen / Clara Marín Briggiler

INTEGRATING IMMUNOREGULATORY AND VASCULAR SIGNALING PROGRAMS THROUGH LECTIN-GLYCAN INTERACTIONS DIEGO CROCI

Institute of Histology and Embryology of Mendoza Dr. Mario Burgos (CCT-CONICET). Mendoza. Mendoza, Argentina.

Recent efforts toward decoding the glycosylation signature of immune cells have revealed dramatic changes in N- and O-glycan structures during immune cell maturation, activation and differentiation. The responsibility of deciphering these glycosylation changes is assigned to endogenous lectins which expression is dynamically regulated during chronic inflammatory responses. We will discuss recent findings from our laboratory demonstrating the contribution of glycosylation-dependent mechanisms and lectin-glycan interactions to the regulation of a broad range of immunological programs including T cell survival, dendritic cell fate, microglia activation and endothelial cell signaling. These mechanisms, which could be usurped by tumors to evade and thwart immune responses, have been proposed to shift the balance of immune responses and control immune cell tolerance, inflammation and angiogenesis.

THE YIN AND YANG OF HISTAMINE IN THE REGULATION OF TESTICULAR LEYDIG CELL PROLIFERATION

CAROLINA MONDILLO

Laboratory of Molecular Endocrinology and Signal Transduction. Experimental Medicine and Biology Institute (IByME CONICET). Buenos Aires, Argentina.

Histamine (HA) is a biogenic amine with indisputable significance for medicine and biology. It is synthesized exclusively by histidine decarboxylase (HDC) in all

mammalian tissues, albeit tissue-specific mechanisms operate to keep its concentration within strict limits: both a deficit of HA or a slight excess can lead to health loss. With regard to the male gonad, previous studies have linked increased mast cell numbers and mast-cell related HA with the pathogenesis of infertility. In contrast, HA levels are normally higher in the neonatal testis, and in a former report we described that HDC gene knockout mice show reduced testis weight already at 7 days of age, implying that important HA-dependent events may occur during testicular development. To assess this apparent conflict and considering the ubiquitous role of HA as modulator of cell proliferation, we speculated that testicular HA might contribute to the regulation of LC number. Firstly, we studied the effect of intratesticular HA treatment in adult male rats injected with the specific LC cytotoxic agent ethane dimethanesulphonate (EDS), a convenient model to study normal LC proliferation and development from LC precursors in vivo. As expected, LC re-population was faster in HA-treated rats. Thus, to better identify the stage/s of testicular development in which HA would play a role, we conducted in vitro experiments to evaluate its effect on the proliferation of progenitor and

immature LC, isolated from 21- and 35-day old male rats, respectively. However, none exhibited a proliferative response upon stimulation with HA. We then studied HDC immunoexpression in testes of rats aged 7 to 240 days, and found that it was highest in 7day old rats but then decreased abruptly, with remnants of the fetal LC population being the most intensively stained. In line with previous observations in HDC KO mice, these results suggest that local HA synthesis may be important to influence LC numbers in the early stages of normal testicular development, while it would be negatively regulated with age. Interestingly, we have recently detected HDC overexpression in 2 murine Levdig tumor cell lines, as well as in human LC hyperplasia and prepubertal LC tumors. Moreover, HA promoted the proliferation of Leydig tumor cells in vitro, while specific HDC inhibitors had the opposite effect. Importantly, these findings indicate that autocrine overproduction of HA might be related to abnormally increased proliferation in LC.

UNDERSTANDING THE CRITICAL ROLE OF MONOCYTE-MACROPHAGE LINEAGE IN INFLAMMATORY DISEASES AND HOW THE COOPERATION WITH OTHER CELL TYPES DEFINE THE EFFECTOR RESPONSE

EUGENIO CARRERA SILVA

Experimental Thrombosis Laboratory, Institute of Experimental Medicine (IMEX), National Academy of Medicine - CONICET. Buenos Aires, Argentina.

Monocyte-macrophage lineage cells are multifunctional and found in nearly all tissues throughout the body. They orchestrate the initiation and resolution phases of both innate and adaptive immunity, significantly impacting protective immunity and immune-mediated pathological damage through their ability to adopt distinct functional capacities in different microenvironment. A major goal of the macrophage field is to link specific functions with specific cellular and molecular pathways associated with different macrophage activation profiles. Negative regulatory feedback is a critical aspect of the homeostatic immune response and disruption on this point could lead to inflammatory-based disease. The tyrosine kinase receptors TYRO3, AXL and MERTK (TAM) and their ligands Protein S (PROS1) and growth arrestspecific 6 (GAS6) are critical players in maintaining immune homeostasis by dampening inflammatory response, mediate efferocytosis and to contribute to tissue repair process. Our research is focus in understanding the participation of monocytemacrophage compartment and TAM axis in the protection or development of some chronic inflammatory human diseased such as Inflammatory Bowel disease, Langerhans Cell Histiocytosis or Multiple Sclerosis as well as in acute infection and sepsis. We have found that monocyte-macrophage linage play central role not only in immune-mediated diseases but also because regulatory T cell or platelets can orchestrate macrophage effector responses improving clinical outcome.

DECONSTRUCTING THE GLUCOCORTICOID RECEPTOR: PHARMACOLOGICAL IMPLICATIONS

DIEGO PRESMAN

Institute of Physiology, Molecular Biology and Neurosciences (IFIBYNE-UBA-CONICET). Buenos Aires, Argentina.

Synthetic glucocorticoids (GCs) are one of the most prescribed pharmaceuticals world-wide due to their powerful anti-inflammatory and immunosuppressive activities. The action of GCs is mediated by the glucocorticoid receptor (GR), a member of the nuclear receptor superfamily of transcription factors. The GR is involved in many physiological processes, including the regulation of cell death and proliferation. Historically, GR transcriptional activity and clinical outcomes have been linked to its dimeric/monomeric state. A widely discussed model suggests that dimeric GR regulates unfavorable metabolic pathways, while monomeric GR is responsible for anti-inflammatory activities. Hence, GR ligands that preferentially induce the monomeric rather than the dimeric pathway should retain the desired pharmacological effects but will lack the undesired adverse reactions. However, the search for improved ligands under this paradigm has produced no significant results for the last 25 years. During this talk, I will present evidence against this predominant "dissociated model". By combining advance quantitative fluorescence microscopy techniques with genomic analysis on oligomeric mutant receptors, I will propose a new relationship between GR's guaternary